NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Some have argued that median OS for newly diagnosed GBM patients receiving SOC has already moved on from 18 months to nearer 2 years.

Clearly not the case going by the Optune trial data.

Optune represents a marginal benefit at best, with a median OS of of 19.4 months, and control arm median OS of 16.6 months, in their Phase 3 trial.
The majority of treatment participants were deceased at 2 years.

Optune has no systemic or curative effect.